US venture capital valuations have, in some respects, begun to reflect broader market uncertainty, but certain stages and sectors have proven remarkably resilient as some startups remain able to demonstrate their potential for value creation. .
Our Second Quarter 2022 U.S. Venture Capital Valuations Report, sponsored by Silicon Valley Bank, shows how investor sentiment has and hasn’t changed over the past quarter, and what that may mean for the future. trade size, liquidity and more throughout the year.
Key points to remember
- Early-stage pre-money median valuations showed signs of contraction, posting their first quarter-on-quarter decline in more than two years, falling 16% in the second quarter to $52 million.
- Seed-stage investing has held up better than at any other stage, with the number and size of deals remaining high and median pre-silver valuations up 33% this year compared to 2021.
- Non-traditional investors focused their more cautious behavior on the high end of the market. The upper quartiles of deal size participation and valuation both fell more than 13% in the first half, but such declines are not present at the medians.
- Only 10 public listings of companies valued at more than $1 billion have been recorded through June 30, compared to more than 100 in 2021, as the public market climate continues to put pressure on exit valuations.
This report was sponsored by Silicon Valley Bank. Would you like to sponsor future editions of this report? Visit our media partnerships page to learn more.
|Key points to remember||4|
|angel and seed||5|
|Early stage venture capital assessments||seven|
|Late-stage venture capital assessments||9|
|Biotech & pharmaceutical||11|
|Terms of the offer||21|